Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis

References

• Falco-Walter JJ, Scheffer IE, Fisher RS. The new definition and classification of seizures and epilepsy. Epilepsy Res. 2017 Nov 28;139:73–79. doi: 10.1016/j.eplepsyres.2017.11.015
   PubMedGoogle Scholar
• Loscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013 Oct;12(10):757–776. doi: 10.1038/nrd4126
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018 Mar 1;75(3):279–286. doi: 10.1001/jamaneurol.2017.3949
   PubMed Web of Science ®Google Scholar
• Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia. 2001 Apr;42(4):515–524. doi: 10.1046/j.1528-1157.2001.28900.x
   PubMed Web of Science ®Google Scholar
• Temkin NR, Jarell AD, Anderson GD. Antiepileptogenic agents: how close are we? Drugs. 2001;61(8):1045–1055. doi: 10.2165/00003495-200161080-00002
   PubMed Web of Science ®Google Scholar
• Barker-Haliski ML, Friedman D, French JA, et al. Disease modification in epilepsy: from animal models to clinical applications. Drugs. 2015 May;75(7):749–767. doi: 10.1007/s40265-015-0395-9
   PubMed Web of Science ®Google Scholar
• Trinka E, Brigo F. Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward. Curr Opin Neurol. 2014 Apr;27(2):227–235. doi: 10.1097/WCO.0000000000000067
   PubMed Web of Science ®Google Scholar
• Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15;168:107966. doi: 10.1016/j.neuropharm.2020.107966
   PubMed Web of Science ®Google Scholar
• Barker-Haliski M, Sills GJ, White HS. What are the arguments for and against rational therapy for epilepsy? Advances in experimental medicine and biology. Adv Exp Med Biol. 2014;813:295–308. PMID 25012386.
   PubMedGoogle Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fifteenth eilat conference on new antiepileptic drugs and devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia. 2020 Nov;61(11):2340–2364. doi: 10.1111/epi.16725
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fifteenth eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020 Nov;61(11):2365–2385. doi: 10.1111/epi.16726
   PubMed Web of Science ®Google Scholar
• Pauletti A, Terrone G, Shekh-Ahmad T, et al. Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain. 2017 May 30;140(7):1885–1899. doi: 10.1093/brain/awx117
   PubMedGoogle Scholar
• Iori V, Iyer AM, Ravizza T, et al. Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiol Dis. 2017 Mar;99:12–23. doi: 10.1016/j.nbd.2016.12.007
   PubMed Web of Science ®Google Scholar
• Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011 Nov;4(6):385–407. doi: 10.1177/1756285611417920
   PubMedGoogle Scholar
• Loscher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016 Oct;126:157–184. doi: 10.1016/j.eplepsyres.2016.05.016
   PubMed Web of Science ®Google Scholar
• White HS, Smith-Yockman M, Srivastava A, et al. Therapeutic assays for the identification and characterization of antiepileptic and antiepileptogenic drugs. In: Pitkanen A, Schwartzkroin P Moshe S, editors. Models of Seizure and Epilepsy. 1 ed. Burlington (MA): Elsevier Academic Press; 2006. p. 539–549.
   Google Scholar
• Jones A, Barker-Haliski M, Ilie AS, et al. A multiorganism pipeline for antiseizure drug discovery: identification of chlorothymol as a novel γ-aminobutyric acidergic anticonvulsant. Epilepsia. 2020 Aug 14;61(10):2106–2118. doi: 10.1111/epi.16644
   PubMedGoogle Scholar
• Barker-Haliski M, White HS. Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening. Neuropharmacology. 2019 Aug 27;167:107750. doi: 10.1016/j.neuropharm.2019.107750
   PubMedGoogle Scholar
• Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009 Feb;50 Suppl 2(s2):10–13. doi: 10.1111/j.1528-1167.2008.02005.x
   PubMedGoogle Scholar
• Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA. 1991 Mar 13;265(10):1271–1277. doi: 10.1001/jama.1991.03460100073027
   PubMed Web of Science ®Google Scholar
• Council N. A report of the NINDS epilepsy therapy screening program working group, of the national advisory neurological disorders and stroke (NANDS) council. 2020.
   Google Scholar
• Galanopoulou AS, Wong M, Binder D, et al. 2014 epilepsy benchmarks area II: prevent epilepsy and its progression. Epilepsy Curr/Am Epilepsy Soc. 2016 May;16(3):187–191. doi: 10.5698/1535-7511-16.3.187
   PubMedGoogle Scholar
• Vasquez A, Buraniqi E, Wirrell EC. New and emerging pharmacologic treatments for developmental and epileptic encephalopathies. Curr Opin Neurol. 2022 Apr 1;35(2):145–154. doi: 10.1097/WCO.0000000000001029
   PubMedGoogle Scholar
• Del Pozo A, Lehmann L, Knox KM, et al. Can old animals reveal new targets? The aging and degenerating brain as a new precision medicine opportunity for epilepsy. Front Neurol. 2022;13:833624. doi: 10.3389/fneur.2022.833624
   PubMedGoogle Scholar
• Barker-Haliski M, Knox K, Zierath DK, et al. Development of an antiepileptogenesis drug screening platform: effects of everolimus and phenobarbital. Epilepsia. 2021;62(7):1677–1688. PMID: 34080183.
   PubMedGoogle Scholar
• Loscher W. Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res. 2017 Jul;42(7):1873–1888. doi: 10.1007/s11064-017-2222-z
   PubMed Web of Science ®Google Scholar
• Vande Vyver M, Barker-Haliski M, Aourz N, et al. Higher susceptibility to 6 hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer’s disease. Epilepsia. 2022 Jun 30;63(10):2703–2715. doi: 10.1111/epi.17355
   PubMedGoogle Scholar
• Bartolini E. Inherited Developmental and Epileptic Encephalopathies. Neurol Int. 2021;13(4):555–568. doi: 10.3390/neurolint13040055
   PubMedGoogle Scholar
• Begley CE, Durgin TL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia. 2015 Sep;56(9):1376–1387. doi: 10.1111/epi.13084
   PubMed Web of Science ®Google Scholar
• Drugs CP-O. US code of federal regulations part 316 - orphan drugs. 1992 Dec 29.
   Google Scholar
• Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998 Jul 24;353(2–3):191–206. doi: 10.1016/S0014-2999(98)00410-5
   PubMed Web of Science ®Google Scholar
• Patra PH, Barker-Haliski M, White HS, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019 Feb;60(2):303–314. doi: 10.1111/epi.14629
   PubMed Web of Science ®Google Scholar
• Nishi T, Metcalf CS, Fujimoto S, et al. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor. Epilepsia. 2022 Jun;63(6):1580–1590. doi: 10.1111/epi.17232
   PubMed Web of Science ®Google Scholar
• Barton ME, Klein BD, Wolf HH, et al. Pharmacological characterization of the 6 hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47(3):217–227. doi: 10.1016/S0920-1211(01)00302-3
   PubMed Web of Science ®Google Scholar
• Koneval Z, Knox K, Memon A, et al. Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred versus inbred mice. Epilepsia. 2020;(9):2022–2034. doi: 10.1111/epi.16624
   PubMedGoogle Scholar
• Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol. 1992 Nov 10;222(2–3):193–203. doi: 10.1016/0014-2999(92)90855-X
   PubMed Web of Science ®Google Scholar
• Del Pozo A, Barker-Haliski M. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Exp Neurol. 2022 Nov 26;360:114288. doi: 10.1016/j.expneurol.2022.114288
   PubMedGoogle Scholar
• Barker-Haliski ML, Loscher W, White HS, et al. Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy. Epilepsia. 2017 Jul;58 Suppl 3(S3):39–47. doi: 10.1111/epi.13785
   PubMedGoogle Scholar
• Metcalf CS, Vanegas F, Underwood T, et al. Screening of prototype antiseizure and anti-inflammatory compounds in the Theiler’s murine encephalomyelitis virus model of epilepsy. Epilepsia Open. 2022 Mar;7(1):46–58. doi: 10.1002/epi4.12550
   PubMedGoogle Scholar
• Patel DC, Wallis G, Fujinami RS, et al. Cannabidiol reduces seizures following CNS infection with Theiler’s murine encephalomyelitis virus. Epilepsia Open. 2019 Sep;4(3):431–442. doi: 10.1002/epi4.12351
   PubMedGoogle Scholar
• Barker-Haliski M, Nishi T, White HS. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler’s virus infection in mice. Neuropharmacology. 2023 Jan 1;222:109310. doi: 10.1016/j.neuropharm.2022.109310
   PubMedGoogle Scholar
• Hawkins NA, Anderson LL, Gertler TS, et al. Screening of conventional anticonvulsants in a genetic mouse model of epilepsy. Ann Clin Transl Neurol. 2017 May;4(5):326–339. doi: 10.1002/acn3.413
   PubMedGoogle Scholar
• Patra PH, Serafeimidou-Pouliou E, Bazelot M, et al. Cannabidiol improves survival and behavioural co-morbidities of dravet syndrome in mice. Br J Pharmacol. 2020 Jun;177(12):2779–2792. doi: 10.1111/bph.15003
   PubMedGoogle Scholar
• Hawkins NA, Jurado M, Thaxton TT, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in dravet syndrome mice. Epilepsia. 2021 Nov;62(11):2845–2857. doi: 10.1111/epi.17062
   PubMed Web of Science ®Google Scholar
• Nishi T, Kondo S, Miyamoto M, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020 Oct 13;10(1):17081. doi: 10.1038/s41598-020-74036-6
   PubMed Web of Science ®Google Scholar
• Wu YW, Sullivan J, McDaniel SS, et al. Incidence of dravet syndrome in a US population. Pediatrics. 2015 Nov;136(5):e1310–5. doi: 10.1542/peds.2015-1807
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of dravet syndrome. Epilepsia. 2022 Jul;63(7):1761–1777. doi: 10.1111/epi.17274
   PubMed Web of Science ®Google Scholar
• Ricobaraza A, Mora-Jimenez L, Puerta E, et al. Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent dravet syndrome SCN1A missense mutation. Sci Rep. 2019 Oct 2;9(1):14172. doi: 10.1038/s41598-019-50627-w
   PubMedGoogle Scholar
• Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006 Sep;9(9):1142–1149. doi: 10.1038/nn1754
   PubMed Web of Science ®Google Scholar
• Miller AR, Hawkins NA, McCollom CE, et al. Mapping genetic modifiers of survival in a mouse model of dravet syndrome. Genes Brain Behav. 2014 Feb;13(2):163–172. doi: 10.1111/gbb.12099
   PubMedGoogle Scholar
• Ogiwara I, Miyamoto H, Morita N, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007 May 30;27(22):5903–5914. doi: 10.1523/JNEUROSCI.5270-06.2007
   PubMed Web of Science ®Google Scholar
• Pernici CD, Mensah JA, Dahle EJ, et al. Development of an antiseizure drug screening platform for dravet syndrome at the NINDS contract site for the epilepsy therapy screening program. Epilepsia. 2021 Jul;62(7):1665–1676. doi: 10.1111/epi.16925
   PubMed Web of Science ®Google Scholar
• Quinn S, Brusel M, Ovadia M, et al. Acute effect of antiseizure drugs on background oscillations in Scn1a (A1783V) dravet syndrome mouse model. Front Pharmacol. 2023;14:1118216. doi: 10.3389/fphar.2023.1118216
   PubMedGoogle Scholar
• Oakley JC, Cho AR, Cheah CS, et al. Synergistic GABA-enhancing therapy against seizures in a mouse model of dravet syndrome. J Pharmacol Exp Ther. 2013 May;345(2):215–224. doi: 10.1124/jpet.113.203331
   PubMedGoogle Scholar
• Wong JC, Dutton SB, Collins SD, et al. Huperzine a provides robust and sustained protection against induced seizures in Scn1a mutant mice. Front Pharmacol. 2016;7:357. doi: 10.3389/fphar.2016.00357
   PubMed Web of Science ®Google Scholar
• Han Z, Chen C, Christiansen A, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of dravet syndrome. Sci Transl Med. 2020 Aug 26;12(558). doi: 10.1126/scitranslmed.aaz6100
   Web of Science ®Google Scholar
• Tanenhaus A, Stowe T, Young A, et al. Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a dravet syndrome mouse model and is well tolerated in nonhuman primates. Hum Gene Ther. 2022 Jun;33(11–12):579–597. doi: 10.1089/hum.2022.037
   PubMed Web of Science ®Google Scholar
• Cao D, Ohtani H, Ogiwara I, et al. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of dravet syndrome. Epilepsia. 2012 Jul;53(7):1140–1145. doi: 10.1111/j.1528-1167.2012.03497.x
   PubMed Web of Science ®Google Scholar
• Hawkins NA, Zachwieja NJ, Miller AR, et al. Fine mapping of a dravet syndrome modifier locus on mouse chromosome 5 and candidate gene analysis by RNA-Seq. PLOS Genet. 2016 Oct;12(10):e1006398. doi: 10.1371/journal.pgen.1006398
   PubMedGoogle Scholar
• Anderson LL, Ametovski A, Lin Luo J, et al. Cannabichromene, related phytocannabinoids, and 5-fluoro-cannabichromene have anticonvulsant properties in a mouse model of dravet syndrome. ACS Chem Neurosci. 2021 Jan 20;12(2):330–339. doi: 10.1021/acschemneuro.0c00677
   PubMedGoogle Scholar
• Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019 Nov;60(11):2224–2234. doi: 10.1111/epi.16355
   PubMed Web of Science ®Google Scholar
• Anderson LL, Everett-Morgan D, Petkova SP, et al. Ictal vocalizations in the Scn1a(±) mouse model of dravet syndrome. Epilepsia Open. 2023 Sep;8(3):776–784. doi: 10.1002/epi4.12715
   PubMedGoogle Scholar
• Kaplan JS, Stella N, Catterall WA, et al. Cannabidiol attenuates seizures and social deficits in a mouse model of dravet syndrome. Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11229–11234. doi: 10.1073/pnas.1711351114
   PubMed Web of Science ®Google Scholar
• Cha J, Filatov G, Smith SJ, et al. Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of dravet syndrome. Epilepsia Open. 2024 Feb;9(1):300–313. doi: 10.1002/epi4.12873
   PubMedGoogle Scholar
• Klein BD, Jacobson CA, Metcalf CS, et al. Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP). Neurochem Res. 2017 Jul;42(7):1939–1948. doi: 10.1007/s11064-017-2287-8
   PubMed Web of Science ®Google Scholar
• Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol. 1981 Aug;21(S1):437S–448S. doi: 10.1002/j.1552-4604.1981.tb02624.x
   PubMedGoogle Scholar
• Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993 Mar 2;232(2–3):147–158. doi: 10.1016/0014-2999(93)90768-D
   PubMed Web of Science ®Google Scholar
• Gower AJ, Hirsch E, Boehrer A, et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995 Nov;22(3):207–213. doi: 10.1016/0920-1211(95)00077-1
   PubMed Web of Science ®Google Scholar
• Wilcox KS, West PJ, Metcalf CS. The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020 Apr;166:107811. doi: 10.1016/j.neuropharm.2019.107811
   PubMed Web of Science ®Google Scholar
• Kehne JH, Klein BD, Raeissi S, et al. The national institute of neurological disorders and stroke (NINDS) epilepsy therapy screening program (ETSP). Neurochem Res. 2017 May 2;42(7):1894–1903. doi: 10.1007/s11064-017-2275-z
   PubMed Web of Science ®Google Scholar
• Barker-Haliski ML, Johnson K, Billingsley P, et al. Validation of a preclinical drug screening platform for pharmacoresistant epilepsy. Neurochem Res. 2017 Jul;42(7):1904–1918. doi: 10.1007/s11064-017-2227-7
   PubMedGoogle Scholar
• Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci. 2000;23(9):393–398. doi: 10.1016/S0166-2236(00)01629-5
   PubMed Web of Science ®Google Scholar
• Biervert C, Steinlein OK. Structural and mutational analysis of KCNQ2, the major gene locus for benign familial neonatal convulsions. Hum Genet. 1999 Mar;104(3):234–240. doi: 10.1007/PL00008713
   PubMedGoogle Scholar
• Pisano T, Numis AL, Heavin SB, et al. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia. 2015 May;56(5):685–691. doi: 10.1111/epi.12984
   PubMed Web of Science ®Google Scholar
• Numis AL, Angriman M, Sullivan JE, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology. 2014 Jan 28;82(4):368–370. doi: 10.1212/WNL.0000000000000060
   PubMed Web of Science ®Google Scholar
• Sands TT, Balestri M, Bellini G, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016 Dec;57(12):2019–2030. doi: 10.1111/epi.13596
   PubMed Web of Science ®Google Scholar
• Knight D, Mahida S, Kelly M, et al. Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy. Epilepsia. 2023 Jul;64(7):e143–e147. doi: 10.1111/epi.17627
   PubMedGoogle Scholar
• Watanabe H, Nagata E, Kosakai A, et al. Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J Neurochem. 2000 Jul;75(1):28–33. doi: 10.1046/j.1471-4159.2000.0750028.x
   PubMed Web of Science ®Google Scholar
• Otto JF, Yang Y, Frankel WN, et al. Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel [research support, non-U.S. Gov’t research support, U.S. Gov’t, P.H.S.]. Epilepsia. 2004 Sep;45(9):1009–1016. doi: 10.1111/j.0013-9580.2004.65703.x
   PubMed Web of Science ®Google Scholar
• Bast T, Ramantani G, Seitz A, et al. Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults. Acta Neurol Scand. 2006 Feb;113(2):72–81. doi: 10.1111/j.1600-0404.2005.00555.x
   PubMed Web of Science ®Google Scholar
• Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia. 2011 Jan;52(1):158–174. doi: 10.1111/j.1528-1167.2010.02777.x
   PubMed Web of Science ®Google Scholar
• Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015 Jun;5(6):a022426–a022426. doi: 10.1101/cshperspect.a022426
   PubMed Web of Science ®Google Scholar
• Kim JK, Lee JH. Mechanistic target of rapamycin pathway in epileptic disorders. J Korean Neurosurg Soc. 2019 May;62(3):272–287. doi: 10.3340/jkns.2019.0027
   PubMedGoogle Scholar
• Rademacher S, Eickholt BJ. PTEN in autism and neurodevelopmental disorders. Cold Spring Harb Perspect Med. 2019 Nov 1;9(11):a036780. doi: 10.1101/cshperspect.a036780
   PubMed Web of Science ®Google Scholar
• Lee WS, Baldassari S, Chipaux M, et al. Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia. Ann Clin Transl Neurol. 2021 Feb;8(2):485–490. doi: 10.1002/acn3.51286
   PubMedGoogle Scholar
• Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol. 2016 Jul;12(7):379–392. doi: 10.1038/nrneurol.2016.81
   PubMed Web of Science ®Google Scholar
• Carter AN, Born HA, Levine AT, et al. Wortmannin attenuates seizure-induced hyperactive PI3K/Akt/mTOR signaling, impaired memory, and spine dysmorphology in rats. eNeuro. 2017 May;4(3):ENEURO.0354–16.2017. doi: 10.1523/ENEURO.0354-16.2017
   PubMedGoogle Scholar
• Nguyen LH, Mahadeo T, Bordey A. mTOR hyperactivity levels influence the severity of epilepsy and associated neuropathology in an experimental Model of tuberous sclerosis complex and focal cortical dysplasia. J Neurosci. 2019 Apr 3;39(14):2762–2773. doi: 10.1523/JNEUROSCI.2260-18.2019
   PubMed Web of Science ®Google Scholar
• Yang MT, Lin YC, Ho WH, et al. Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures. J Neuroinflammation. 2017 Jan 21;14(1):15. doi: 10.1186/s12974-017-0797-6
   PubMedGoogle Scholar
• Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia. 2010 Jan;51(1):27–36. doi: 10.1111/j.1528-1167.2009.02341.x
   PubMed Web of Science ®Google Scholar
• Roy A, Skibo J, Kalume F, et al. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. Elife. 2015 Dec 3;4. doi: 10.7554/eLife.12703
   Google Scholar
• Roy A, Han VZ, Bard AM, et al. Non-synaptic cell-autonomous mechanisms underlie neuronal hyperactivity in a genetic model of PIK3CA-Driven intractable epilepsy. Front Mol Neurosci. 2021;14:772847. doi: 10.3389/fnmol.2021.772847
   PubMedGoogle Scholar
• Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022 Jun;63(6):1475–1499. doi: 10.1111/epi.17236
   PubMed Web of Science ®Google Scholar
• Grosso S, Galimberti D, Vezzosi P, et al. Childhood absence epilepsy: evolution and prognostic factors. Epilepsia. 2005 Nov;46(11):1796–1801. doi: 10.1111/j.1528-1167.2005.00277.x
   PubMedGoogle Scholar
• Zhao X, He Z, Li Y, et al. Atypical absence seizures and gene variants: a gene-based review of etiology, electro-clinical features, and associated epilepsy syndrome. Epilepsy & Behav. 2024 Feb;151:109636. doi: 10.1016/j.yebeh.2024.109636
   PubMedGoogle Scholar
• Noebels JL, Sidman RL. Inherited epilepsy: spike-wave and focal motor seizures in the mutant mouse tottering. Science. 1979 Jun 22;204(4399):1334–1336. doi: 10.1126/science.572084
   PubMed Web of Science ®Google Scholar
• Fletcher CF, Lutz CM, O’Sullivan TN, et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell. 1996 Nov 15;87(4):607–617. doi: 10.1016/S0092-8674(00)81381-1
   PubMed Web of Science ®Google Scholar
• Chen W, Cai ZL, Chao ES, et al. Stxbp1/Munc18-1 haploinsufficiency impairs inhibition and mediates key neurological features of STXBP1 encephalopathy. Elife. 2020 Feb 19;9. doi: 10.7554/eLife.48705
   Google Scholar
• Bortolami A, Yu W, Forzisi E, et al. Integrin-KCNB1 potassium channel complexes regulate neocortical neuronal development and are implicated in epilepsy. Cell Death Differ. 2023 Mar;30(3):687–701. doi: 10.1038/s41418-022-01072-2
   PubMedGoogle Scholar
• Speca DJ, Ogata G, Mandikian D, et al. Deletion of the Kv2.1 delayed rectifier potassium channel leads to neuronal and behavioral hyperexcitability. Genes Brain Behav. 2014 Apr;13(4):394–408. doi: 10.1111/gbb.12120
   PubMed Web of Science ®Google Scholar
• Hawkins NA, Misra SN, Jurado M, et al. Epilepsy and neurobehavioral abnormalities in mice with a dominant-negative KCNB1 pathogenic variant. Neurobiol Dis. 2021 Jan;147:105141. doi: 10.1016/j.nbd.2020.105141
   PubMedGoogle Scholar
• Collaborators GBDE, Giussani G, Nichols E. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet Neurol. 2019 Apr;18(4):357–375. doi: 10.1016/S1474-4422(18)30454-X
   PubMed Web of Science ®Google Scholar
• Lehmann L, Lo A, Knox KM, et al. Alzheimer’s disease and Epilepsy: a perspective on the opportunities for overlapping therapeutic innovation. Neurochem Res. 2021 Apr 30;46(8):1895–1912. doi: 10.1007/s11064-021-03332-y
   PubMedGoogle Scholar
• Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of alzheimer disease. JAMA Neurol. 2013 Sep 1;70(9):1158–1166. doi: 10.1001/jamaneurol.2013.136
   PubMed Web of Science ®Google Scholar
• Zarea A, Charbonnier C, Rovelet-Lecrux A, et al. Seizures in dominantly inherited alzheimer disease. Neurology. 2016 Aug 30;87(9):912–919. doi: 10.1212/WNL.0000000000003048
   PubMed Web of Science ®Google Scholar
• Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron. 2007 Sep 6;55(5):697–711. doi: 10.1016/j.neuron.2007.07.025
   PubMed Web of Science ®Google Scholar
• Beckman M, Knox K, Koneval Z, et al. Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition. Neurobiol Dis. 2020 Mar;136:104719. doi: 10.1016/j.nbd.2019.104719
   PubMedGoogle Scholar
• Vande Vyver M, Barker-Haliski M, Aourz N, et al. Higher susceptibility to 6 hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer’s disease. Epilepsia. 2022 Oct;63(10):2703–2715. doi: 10.1111/epi.17355
   PubMedGoogle Scholar
• Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proc Natl Acad Sci USA. 2012;109(42):E2895–903. doi: 10.1073/pnas.1121081109
   PubMed Web of Science ®Google Scholar
• Del Pozo A, Knox KM, Lehmann LM, et al. Chronic evoked seizures in young pre-symptomatic APP/PS1 mice induce serotonin changes and accelerate onset of Alzheimer’s disease-related neuropathology. Prog Neurobiol. 2024 Mar 13;235:102591. doi: 10.1016/j.pneurobio.2024.102591
   PubMedGoogle Scholar
• Ziyatdinova S, Ronnback A, Gurevicius K, et al. Increased epileptiform EEG activity and decreased seizure threshold in arctic APP transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2016;13(7):817–830. doi: 10.2174/1567205013666160129095508
   PubMedGoogle Scholar
• Ziyatdinova S, Viswanathan J, Hiltunen M, et al. Reduction of epileptiform activity by valproic acid in a mouse model of Alzheimer’s disease is not long-lasting after treatment discontinuation. Epilepsy Res. 2015 May;112:43–55. doi: 10.1016/j.eplepsyres.2015.02.005
   PubMed Web of Science ®Google Scholar
• Ziyatdinova S, Gurevicius K, Kutchiashvili N, et al. Spontaneous epileptiform discharges in a mouse model of Alzheimer’s disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res. 2011 Mar;94(1–2):75–85. doi: 10.1016/j.eplepsyres.2011.01.003
   PubMed Web of Science ®Google Scholar
• Johnson EL, Krauss GL, Lee AK, et al. Association Between Midlife Risk Factors and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study. JAMA Neurol. 2018;75(11):1375–1382. doi: 10.1001/jamaneurol.2018.1935
   PubMed Web of Science ®Google Scholar
• Kelly KM. Aging models of acute seizures and epilepsy. Epilepsy Curr/Am Epilepsy Soc. 2010 Jan;10(1):15–20. doi: 10.1111/j.1535-7511.2009.01341.x
   PubMedGoogle Scholar
• Yang H, Rajah G, Guo A, et al. Pathogenesis of epileptic seizures and epilepsy after stroke. Neurol Res. 2018 Jun;40(6):426–432. doi: 10.1080/01616412.2018.1455014
   PubMed Web of Science ®Google Scholar
• Wang J, Wu C, Peng J, et al. Early-onset convulsive seizures induced by brain hypoxia-ischemia in aging mice: effects of anticonvulsive treatments. PLOS ONE. 2015;10(12):e0144113. doi: 10.1371/journal.pone.0144113
   PubMedGoogle Scholar
• Klein P, Dingledine R, Aronica E, et al. Commonalities in epileptogenic processes from different acute brain insults: do they translate? Epilepsia. 2018 Jan;59(1):37–66. doi: 10.1111/epi.13965
   PubMed Web of Science ®Google Scholar
• Fordington S, Manford M. A review of seizures and epilepsy following traumatic brain injury. J Neurol. 2020 Oct;267(10):3105–3111. doi: 10.1007/s00415-020-09926-w
   PubMed Web of Science ®Google Scholar
• Yeh CC, Chen TL, Hu CJ, et al. Risk of epilepsy after traumatic brain injury: a retrospective population-based cohort study. J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):441–445. doi: 10.1136/jnnp-2012-302547
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Eastman CL, Darvas F, et al. Mild passive focal cooling prevents epileptic seizures after head injury in rats. Ann Neurol. 2013 Feb;73(2):199–209. doi: 10.1002/ana.23764
   PubMed Web of Science ®Google Scholar
• Santhakumar V, Voipio J, Kaila K, et al. Post-traumatic hyperexcitability is not caused by impaired buffering of extracellular potassium. J Neurosci. 2003 Jul 2;23(13):5865–5876. doi: 10.1523/JNEUROSCI.23-13-05865.2003
   PubMedGoogle Scholar
• Di Sapia R, Moro F, Montanarella M, et al. In-depth characterization of a mouse model of post-traumatic epilepsy for biomarker and drug discovery. Acta Neuropathol Commun. 2021 Apr 26;9(1):76. doi: 10.1186/s40478-021-01165-y
   PubMedGoogle Scholar
• Singh G, Prabhakar S. The association between central nervous system (CNS) infections and epilepsy: epidemiological approaches and microbiological and epileptological perspectives. Epilepsia. 2008 Aug;49 Suppl 6(s6):2–7. doi: 10.1111/j.1528-1167.2008.01749.x
   PubMedGoogle Scholar
• Khetsuriani N, Holman RC, Anderson LJ. Burden of encephalitis-associated hospitalizations in the United States, 1988-1997. Clin Infect Dis. 2002 Jul 15;35(2):175–182. doi: 10.1086/341301
   PubMed Web of Science ®Google Scholar
• Carpio A, and Hauser W. Epilepsy in the developing world. Curr Neurol Neurosci Rep. 2009;9(1):319–326. doi: 10.1007/s11910-009-0048-z#citeas
   PubMedGoogle Scholar
• Annegers JF, Hauser WA, Lee JR, et al. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia. 1995 Apr;36(4):327–333. doi: 10.1111/j.1528-1157.1995.tb01005.x
   PubMed Web of Science ®Google Scholar
• Antony AR, Haneef Z. Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. 2020 Dec;83:234–241. doi: 10.1016/j.seizure.2020.10.014
   PubMed Web of Science ®Google Scholar
• Khedr EM, Shoyb A, Mohammaden M, et al. Acute symptomatic seizures and COVID-19: hospital-based study. Epilepsy Res. 2021 Aug;174:106650. doi: 10.1016/j.eplepsyres.2021.106650
   PubMedGoogle Scholar
• Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. Epilepsia. 2008 Aug;49 Suppl 6(s6):13–18. doi: 10.1111/j.1528-1167.2008.01751.x
   PubMedGoogle Scholar
• Zierath DK, Davidson S, Manoukian J, et al. Diet composition and sterilization modifies intestinal microbiome diversity and burden of Theiler’s virus infection–induced acute seizures. Epilepsia. 2024;65(6):1777–1790. doi: 10.1111/epi.17946
   PubMedGoogle Scholar
• Olson CA, Vuong HE, Yano JM, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018 Jul 12;174(2):497. doi: 10.1016/j.cell.2018.06.051
   PubMed Web of Science ®Google Scholar
• Libbey JE, Doty DJ, Sim JT, et al. The effects of diet on the severity of central nervous system disease: One part of lab-to-lab variability. Nutrition. 2016;32(7–8):877–883. doi: 10.1016/j.nut.2016.01.009
   PubMedGoogle Scholar
• Rho JM. How does the ketogenic diet induce anti-seizure effects? Neurosci Lett. 2017 Jan 10;637:4–10. doi: 10.1016/j.neulet.2015.07.034
   PubMed Web of Science ®Google Scholar
• Hampton T. Gut microbes may account for the anti-seizure effects of the ketogenic diet. JAMA. 2018 Oct 2;320(13):1307. doi: 10.1001/jama.2017.12865
   PubMedGoogle Scholar
• Olson CA, Vuong HE, Yano JM, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018 Jun 14;173(7):1728–1741 e13. doi: 10.1016/j.cell.2018.04.027
   PubMed Web of Science ®Google Scholar
• Leclercq K, Matagne A, Kaminski RM. Low potency and limited efficacy of antiepileptic drugs in the mouse 6 hz corneal kindling model. Epilepsy Res. 2014 May;108(4):675–683. doi: 10.1016/j.eplepsyres.2014.02.013
   PubMed Web of Science ®Google Scholar
• Rowley NM, White HS. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models. Epilepsy Res. 2010 Dec;92(2–3):163–169. doi: 10.1016/j.eplepsyres.2010.09.002
   PubMed Web of Science ®Google Scholar
• Barker-Haliski ML, Vanegas F, Mau MJ, et al. Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice. Epilepsia. 2016 Sep;57(9):1386–1397. doi: 10.1111/epi.13476
   PubMedGoogle Scholar
• Remigio GJ, Loewen JL, Heuston S, et al. Corneal kindled C57BL/6 mice exhibit saturated dentate gyrus long-term potentiation and associated memory deficits in the absence of overt neuron loss. Neurobiol Dis. 2017 Jun 15;105:221–234. doi: 10.1016/j.nbd.2017.06.006
   PubMedGoogle Scholar
• Loewen JL, Barker-Haliski ML, Dahle EJ, et al. Neuronal injury, Gliosis, and glial proliferation in two models of temporal lobe epilepsy. J Neuropathol Exp Neurol. 2016 Apr;75(4):366–378. doi: 10.1093/jnen/nlw008
   PubMed Web of Science ®Google Scholar
• Koneval Z, Knox KM, White HS, et al. Lamotrigine-resistant corneal-kindled mice: a model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery. Epilepsia. 2018 Jun;59(6):1245–1256. doi: 10.1111/epi.14190
   PubMedGoogle Scholar
• Srivastava AK, White HS. Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats. Epilepsy Res. 2013 Mar;104(1–2):26–34. doi: 10.1016/j.eplepsyres.2012.10.003
   PubMed Web of Science ®Google Scholar
• Zierath D, Mizuno S, Barker-Haliski M. Frontline Sodium Channel-Blocking Antiseizure Medicine Use Promotes Future Onset of Drug-Resistant Chronic Seizures. Int J Mol Sci. 2023;24(5):4848. doi: 10.3390/ijms24054848
   PubMedGoogle Scholar
• Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology. 2021 Mar 1;185:108442. doi: 10.1016/j.neuropharm.2020.108442
   PubMedGoogle Scholar
• Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in dravet syndrome. Neurology. 2018 Apr 3;90(14):e1204–e1211. doi: 10.1212/WNL.0000000000005254
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017 May 25;376(21):2011–2020. doi: 10.1056/NEJMoa1611618
   PubMed Web of Science ®Google Scholar
• Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020 May 1;77(5):613–621. doi: 10.1001/jamaneurol.2020.0073
   PubMed Web of Science ®Google Scholar
• Madan Cohen J, Checketts D, Dunayevich E, et al. Time to onset of cannabidiol treatment effects in dravet syndrome: analysis from two randomized controlled trials. Epilepsia. 2021 Sep;62(9):2218–2227. doi: 10.1111/epi.16974
   PubMedGoogle Scholar
• Piredda SG, Woodhead JH, Swinyard EA. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J Pharmacol Exp Ther. 1985;232(3):741–745.
   PubMedGoogle Scholar
• Leppert MF, Singh N. Susceptibility genes in human epilepsy. Semin Neurol. 1999;19(4):397–405. doi: 10.1055/s-2008-1040854
   PubMedGoogle Scholar
• Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential dravet syndrome treatment. Nat Commun. 2013 Sep 3;4(1):2410. doi: 10.1038/ncomms3410
   PubMedGoogle Scholar
• Griffin A, Hamling KR, Knupp K, et al. Clemizole and modulators of serotonin signalling suppress seizures in dravet syndrome. Brain. 2017 Mar 1;140(3):669–683. doi: 10.1093/brain/aww342
   PubMedGoogle Scholar
• Moog M, Baraban SC. Clemizole and trazodone are effective antiseizure treatments in a zebrafish model of STXBP1 disorder. Epilepsia Open. 2022 Sep;7(3):504–511. doi: 10.1002/epi4.12604
   PubMedGoogle Scholar
• Hahn CD, Jiang Y, Villanueva V, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with dravet syndrome or lennox–gastaut syndrome (ELEKTRA). Epilepsia. 2022 Jul 16;63(10):2671–2683. doi: 10.1111/epi.17367
   PubMed Web of Science ®Google Scholar
• Salamone A, Terrone G, Di Sapia R, et al. Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy. Neurobiol Dis. 2022 Oct 15;173:105835. doi: 10.1016/j.nbd.2022.105835
   PubMedGoogle Scholar
• Koike T, Yoshikawa M, Ando HK, et al. Discovery of Soticlestat, a potent and selective inhibitor for cholesterol 24-hydroxylase (CH24H). J Med Chem. 2021 Aug 26;64(16):12228–12244. doi: 10.1021/acs.jmedchem.1c00864
   PubMedGoogle Scholar
• Paul SM, Doherty JJ, Robichaud AJ, et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci. 2013 Oct 30;33(44):17290–17300. doi: 10.1523/JNEUROSCI.2619-13.2013
   PubMed Web of Science ®Google Scholar
• Alexandrov P, Cui JG, Zhao Y, et al. 24S-hydroxycholesterol induces inflammatory gene expression in primary human neural cells. Neuroreport. 2005 Jun 21;16(9):909–913. doi: 10.1097/00001756-200506210-00007
   PubMedGoogle Scholar
• Richards RK, Everett GM. Tridione: a new anticonvulsant drug. J Lab Clin Med. 1946 Dec;31(12):1330–1336.
   PubMedGoogle Scholar